Aptevo Therapeutics Inc. filed a Form 8-K on November 2, 2026, disclosing a prospectus supplement filed October 30, 2026 to offer up to $2,309,834 of common stock under its existing at-the-market sales agreement with Roth Capital Partners, LLC.

Key Highlights

  • New ATM capacity: The prospectus supplement covers shares with an aggregate offering price of up to $2,309,834.
  • Prior sales under the agreement: As of the date of the prospectus supplement, the company had issued and sold 303,157 shares of common stock for aggregate gross sale proceeds of $11.8 million.
  • Sales agent: Roth Capital Partners, LLC acts as sales agent under the At The Market Offering Agreement dated April 28, 2025.
  • Registration statement: The offering is registered under an effective Form S-3 (File No. 333-284969).
  • Legal opinion: Paul Hastings LLP issued a legal opinion relating to the shares, attached as Exhibit 5.1.
  • Signed by: Daphne Taylor, Senior Vice President and Chief Financial Officer.

Aptevo Therapeutics Amends ATM Prospectus to Add Up to $2,309,834 in New Common Stock Capacity

According to the filing, Aptevo Therapeutics Inc. (NASDAQ:APVO) filed a prospectus supplement with the SEC on October 30, 2026, under its effective registration statement on Form S-3 (File No. 333-284969). The supplement relates to the offer and sale of shares of common stock, par value $0.001 per share, having an aggregate offering price of up to $2,309,834. The sales will be conducted under the company's At The Market Offering Agreement, dated April 28, 2025, with Roth Capital Partners, LLC as sales agent.

The company disclosed that as of the date of the prospectus supplement, it had already issued and sold 303,157 shares of common stock under the Sales Agreement and the prior prospectus, generating aggregate gross sale proceeds of $11.8 million. The October 30, 2026 prospectus supplement further amends and supplements a series of prior prospectus supplements filed on April 28, 2025, April 29, 2025, May 22, 2025, and June 20, 2025, according to the filing.

The filing notes that Paul Hastings LLP, described as counsel to the company, issued a legal opinion relating to the shares, with that opinion and consent attached as Exhibit 5.1. The filing also states that it "shall not constitute an offer to sell or a solicitation of an offer to buy the Shares described herein," and that sales will be made only by means of the prospectus. The 8-K was signed by Daphne Taylor, Senior Vice President and Chief Financial Officer, on November 2, 2026.

What Was Disclosed

Aptevo Therapeutics filed an 8-K disclosing a new ATM prospectus supplement for up to $2,309,834 in common stock, noting $11.8 million in prior gross proceeds from 303,157 shares already sold under the same sales agreement with Roth Capital Partners, LLC.